GoodRx says that with the support of a healthcare team, a clear transition plan, and a few cost-saving tools, you can make ...

Orforglipron (pronounced or-for-GLIP-ron) might be a mouthful to say, but Indianapolis-based Eli Lilly and Co. sees this ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

Eli Lilly announced Thursday the successful completion of a phase 3 trial of Orforglipron – the first small-molecule GLP-1 that is administered as a once-daily oral pill. The ACHIEVE-1 trial ...

Eli Lilly's solution was to ditch peptides and find an incredibly small molecule to mimic them, which can bind to the same "pocket" on the GLP-1 receptor that the peptides would target.

More than 65% of participants reached an A1C level below 6.5%. Orforglipron is the first small-molecule GLP-1 therapy to successfully complete a phase 3 trial. Eli Lilly plans to submit for ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

Over the past decade, the global pharmaceutical industry has witnessed a transformation in the treatment landscape for ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...